Medication effects and factors for prescribing


	CV outcome		, seni	ng pathy nropathy	it change	glycemia Precautions
Class / medication	ASCVD	HF	Mo, Leb	, Meia	HAbe	6 ₄₆₀
biguanide metformin (Glucophage)	benefit	*	*	loss	no	GI intolerance (start with low dose to minimize)
SGLT-2 inhibitors (flozins) canagliflozin (Invokana) empagliflozin (Jardiance)	benefit	benefit	benefit	loss	no	UTI, ketoacidosis, genital infections, hypotension, fractures (cana), amputation (cana)
dapagliflozin (Farxiga)	neutral					
ertagliflozin (Steglatro)	*	*	*			
GLP-1 receptor agonists liraglutide (Victoza) semaglutide [†] (Ozempic)	benefit	neutral	benefit	loss	no	GI side effects common pancreatitis
exenatide [†] (Bydureon) lixisenatide (Adlyxin)	neutral	neutral	*			
dulaglutide [†] (Trulicity) exenatide (Byetta)	*	*	*			
DPP-4 inhibitors (gliptins) linagliptin (Tradjenta) sitagliptin (Januvia)	neutral	neutral	*	* no	no	joint pain, pancreatitis
alogliptin (Nesina) saxagliptin (Onglyza)	*	potential risk	*			
Thiazolidinediones (TZD) pioglitazone (Actos)	benefit	increased risk	*	gain	no	bone fractures, bladder cancer
sulfonylureas glyburide (DiaBeta, Glynase)	neutral	*	*	gain	yes	
glipizide (Glucotrol) glimepiride (Amyarl)	*	*	*			
insulin lispro, aspart, glulisine, regular, NPH	*	*	*	gain	yes	
glargine, degludec, detemir	neutral	*	*			

^{*}no data available; †given weekly

Renal dose adjustment is required for metformin, GLP-1s, and SGLT-2 inhibitors.

Visit AlosaHealth.org/Diabetes for more information and resources.

Algorithm for the management of diabetes¹



- * Avoid prescribing a DPP-4 and GLP-1 together.
- ** Basal insulin can be initiated if needed at any point.
- (1) American Diabetes Association. Standards of medical care in diabetes-2019. *Diabetes Care*. 2019;42(Suppl 1):S1-S193.







Pharmaceutical Assistance Contract for the Elderly

Balanced information for better care

These are general recommendations only; specific clinical decisions should be made by the treating physician based on an individual patient's clinical condition. These materials were made possible by the PACE Program of the Department of Aging of the Commonwealth of Pennsylvania. Links to references can be found at AlosaHealth.org.